Governments, civil society, health systems, and the private sector are more engaged in noncommunicable diseases (NCDs) than ever. This is evidenced by the World Health Organization’s Global Action Plan, which calls for 80 percent availability of essential medicines and technologies in private and public facilities by 2025 and the explicit inclusion of NCDs in the Sustainable Development Goals. Global health coalitions have successfully strengthened supply security in other disease areas through technical support, advocacy, and resource mobilization. This unique coalition with a multisectoral origin will focus on reduction of cardiovascular disease risk (diabetes, hypertension, and dyslipidemia).

NCDs are the number one cause of death and disability worldwide, forcing 100 million people in low-resource settings into poverty annually. We can reduce that number by using innovation and existing medicines and products, yet current availability of essential medicines and health products (EMPs) falls far short of what is needed. Approximately 74 percent of NCD-related deaths occur in low- and middle-income countries (LMIC).The World Economic Forum estimates that by 2030, NCDs will cost LMIC US$14 trillion in lost output. Effective treatment is critical, and—fortunately—within reach. Identifying and addressing barriers to accessibility of EMPs for NCDs will increase prosperity and save countless lives. Doing so will play a major role in the global drive to attain universal health coverage.

The need for concentrated, country-focused action for NCDs is clear. The Coalition for Access to NCD Medicines & Products meets this challenge. Come learn why now is the right time for governments, civil society, academia, and the private sector to engage in solving global NCD challenges.